Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kolb

Showing results (81-90 of 279) with videos related to

Pageof 28
Sort By:
The Journal of Rheumatology|April 2, 2021
Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 YearsJanet E Pope, Kobina Quansah, Shazia Hassan, et al.
Lung|July 6, 2016
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted ValueWim A Wuyts, Martin Kolb, Susanne Stowasser, et al.
The European Respiratory Journal|May 19, 2018
What's in a name? That which we call IPF, by any other name would act the sameAthol U Wells, Kevin K Brown, Kevin R Flaherty, et al.
Journal of Thoracic Disease|August 26, 2017
A female patient with recurrent lung lesion and hilar lymphadenopathyYangqing Zhan, Linling Cheng, Gerard Cox, et al.
The European Respiratory Journal|February 16, 2019
Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?Athol U Wells, Kevin K Brown, Kevin R Flaherty, et al.
The European Respiratory Journal|February 12, 2021
The case of methotrexate and the lung: Dr Jekyll and Mr HydeVincent Cottin, Elizabeth Bendstrup, Philippe Bonniaud, et al.
The European Respiratory Journal|June 28, 2018
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosisKevin R Flaherty, Martin Kolb, Carlo Vancheri, et al.
Clinical Rheumatology|May 20, 2023
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trialEric L Matteson, Martin Aringer, Gerd R Burmester, et al.
The European Respiratory Journal|July 10, 2019
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trialsImre Noth, Marlies Wijsenbeek, Martin Kolb, et al.
International Journal of Molecular Sciences|September 10, 2021
Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung DiseasesJulie Tanguy, Lenny Pommerolle, Carmen Garrido, et al.
Pageof 28

Showing results (81-90 of 279) with videos related to

Sort By:
Pageof 28
The Journal of Rheumatology|April 2, 2021
Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 YearsJanet E Pope, Kobina Quansah, Shazia Hassan, et al.
Lung|July 6, 2016
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted ValueWim A Wuyts, Martin Kolb, Susanne Stowasser, et al.
The European Respiratory Journal|May 19, 2018
What's in a name? That which we call IPF, by any other name would act the sameAthol U Wells, Kevin K Brown, Kevin R Flaherty, et al.
Journal of Thoracic Disease|August 26, 2017
A female patient with recurrent lung lesion and hilar lymphadenopathyYangqing Zhan, Linling Cheng, Gerard Cox, et al.
The European Respiratory Journal|February 16, 2019
Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?Athol U Wells, Kevin K Brown, Kevin R Flaherty, et al.
The European Respiratory Journal|February 12, 2021
The case of methotrexate and the lung: Dr Jekyll and Mr HydeVincent Cottin, Elizabeth Bendstrup, Philippe Bonniaud, et al.
The European Respiratory Journal|June 28, 2018
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosisKevin R Flaherty, Martin Kolb, Carlo Vancheri, et al.
Clinical Rheumatology|May 20, 2023
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trialEric L Matteson, Martin Aringer, Gerd R Burmester, et al.
The European Respiratory Journal|July 10, 2019
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trialsImre Noth, Marlies Wijsenbeek, Martin Kolb, et al.
International Journal of Molecular Sciences|September 10, 2021
Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung DiseasesJulie Tanguy, Lenny Pommerolle, Carmen Garrido, et al.
Pageof 28